Gilead's Livdelzi Shows High And Sustained ALP Normalization In 74% Of Primary Biliary Cholangitis Patients At 24 Months In Phase 3 ASSURE Study

– ALP Is a Key Marker of Disease Activity in People Living With PBC, With Elevations Above Normal Associated with Increased Risk of Disease Progression –

– Further Analyses of the Phase 3 ASSURE Study Demonstrate Sustained ALP Normalization and Show Exploratory Outcomes of Stable or Improved Liver Stiffness, Providing Supportive, Long-term Evidence –